DNA methylation, molecular genetic, and linkage studies in prostate cancer

Prostate

Volumn 28, Issue 3 SUPPL. 6, 1996, Pages 36-44

  Jarrard, David F ^a   Bova, G Steven ^a   Isaacs, William B ^a  

^a JOHNS HOPKINS HOSPITAL   (United States)

Author keywords

DNA methylation; linkage analysis; prostate cancer; tumor suppressor

Indexed keywords

CANCER GROWTH; CONFERENCE PAPER; DNA METHYLATION; GENE LOCUS; GENETIC LINKAGE; GENETIC SUSCEPTIBILITY; HETEROZYGOSITY; HUMAN; MALE; PRIORITY JOURNAL; PROSTATE CANCER; TUMOR DIFFERENTIATION; TUMOR SUPPRESSOR GENE;

EID: 0029878651     PISSN: 02704137     EISSN: None     Source Type: Journal    
DOI: 10.1002/(sici)1097-0045(1996)6+<36::aid-pros8>3.0.co;2-i     Document Type: Conference Paper

References (88)

1. Fearon ER, Vogelstein B: A genetic model for colorectal tumorigenesis. [Review] Cell 61:759-767, 1990.
2. Dhom G: Epidemiologic aspects of latent and clinically manifest carcinoma of the prostate. J Clin Res Clin Oncol 106:210-218, 1983.
3. Greenberg NM, Demayo F, Finegold MJ, Medina D, Tilley WD, Aspinall JO, Cunha GR, Donjacour AA, Matusik RJ, Rosen JM: Prostate cancer in a transgenic mouse. Proc Natl Acad Sci USA 92:3439-3443, 1995.
4. Rhim JS, Webber MM, Bello D, Lee MS, Arnstein P, Chen LS, Jay G: Stepwise immortalization and transformation of adult human prostate epithelial cells by a combination of HPV-18 and V-KI-RAS. Proc Natl Acad Sci USA 91:11874-11878, 1994.
5. Weijerman PC, Konig JJ, Wong ST, Niesters HG, Peehl DM: Lipofection-mediated immortalization of human prostatic epithelial cells of normal and malignant origin using human papillomavirus type 18 DNA. Cancer Res 54:5579-5583, 1994.
6. Thompson TC, Southgate J, Kitchener G, Land H: Multistage carcinogenesis induced by ras and myc oncogenes in a reconstituted organ. Cell 56:917-930, 1989.
7. Baylin SB, Makos M, Wu JJ, Yen RW, de Bustros A, Vertino P, Nelkin BD: Abnormal patterns of DNA methylation in human neoplasia: Potential consequences for tumor progression. (Review.) Cancer Cells 3:383-390, 1991.
8. Wingo PA, Tong T, Bolden BA: Cancer statistics, 1995. CA 45:8-30, 1995.
9. Stamey TA, McNeal JE: Adenocarcinoma of the prostate. In Walsh PC, Retik AB, Stamey TA, Vaughan ED (eds): Campbell's Urology. Philadelphia: WB Saunders, 1992, pp 1159-1217.
10. Carter BS, Beaty TH, Steinberg GD, Childs B, Walsh PC: Mendelian inheritance of familial prostate cancer. Proc Natl Acad Sci USA 89:3367-3371, 1992.
11. Groden J, Thliveris A, Samowitz W, Carlson M, Gelbert L, Albertsen H, Joslyn G, Stevens J, Spirio L, Robertson M: Identification and characterization of the familial adenomatous polyposis coli gene. Cell 66:589-600, 1991.
12. Leach FS, Nicolaides NC, Papadopoulos N, Liu B, Jen J, Parsons R, Peltomaki P, Sistonen P, Aaltonen LA, Nystrom-Lahti M: Mutations of a mutS homolog in hereditary nonpolyposis colorectal cancer. Cell 75:1215-1225, 1993.
13. Miki Y, Swensen J, Shattuck-Eidens D, Futreal PA, Harshman K, Tavtigian S, Liu Q, Cochran C, Ding W, Bennett LM, Ballinger DG, Barrett JC, Skolnick MH: A strong candidate for the breast and ovarian carcinoma susceptibility gene BRCA1. Science 266:66-71, 1994.
14. Knudsen AG: All in the (cancer) family. Nature Genet 5:103-104, 1993.
15. Futreal PA, Liu QY, Shattuckeidens D, Cochran C, Harshman K, Tavtigian S, Bennett LM, Haugenstrano A, Swensen J, Miki Y, Eddington K, McClure M, Frye C, Weaverfeldhaus J, Ding W, Gholami Z, Soderkvist P, Terry L, Jhanwar S, Berchuck A, Iglehart JD, Marks J, Ballinger DG, Barrett JC, Skolnick MH: BRCA1 mutations in primary breast and ovarian carcinomas. Science 266:120-122, 1994.
16. Steinberg GD, Carter BS, Beaty TH, Childs B, Walsh PC: Family history and the risk of prostate cancer. Prostate 17:337-347, 1990.
17. Cannon L, Bishop DT, Skolnick M, Hunt S, Lyon JL, Smart CR: Genetic epidemiology of prostate cancer in the Utah Mormon genealogy. Cancer Surv 1:47-69, 1982.
18. Morganti G, Cianferrari L, Cresseri A, Arrigoni G, Lovati F: Recherches clinico-statistiques of génétiques sur les néoplasies de la prostate. Acat Genet Stat 6:304-305, 1956.
19. Schuman LM, Mandel J, Blackard C, Bauer H, Scarlett J, McHugh R: Epidemiologic study of prostate cancer: Preliminary report. Cancer Treat Repo 61:181-186, 1971.
20. Spitz MR, Currier RD, Fueger JJ, Babaian RJ, Newell GR: Familial patterns of prostate cancer: A case-control analysis. J Urol 146:1305-1307, 1991.
21. Carter BS, Bova GS, Beaty TH, Steinberg GD, Childs B, Isaacs WB, Walsh PC: Hereditary prostate cancer: epidemiologic and clinical features. [Review.] J Urol 150:797-802, 1993.
22. Bastacky SI, Wojno KJ, Walsh PC, CarMichael MJ, Epstein JI: Pathological features of hereditary prostate cancer. J Urol 153:987-992, 1995.
23. Lee W-H, Morton RA, Epstein JI, Brooks JD, Campbell PA, Bova GS, Hsieh W-S, Isaacs WB, Nelson WG: Cyridine methylation of regulatory sequences near the π-class glutathione-s-transferase gene accompanies human prostate cancer carcinogenesis. Proc Natl Acad Sci USA 91:11733-11737, 1994.
24. Rideout WM, Eversolecire P, Spruck CH, Hustad CM, Coetzee GA, Gonzales FA, Jones PA: Progressive increase in the methylation status and heterochromatinization of the myo D CpG island during oncogenic transformation. Mol Cell Biol 14:6143-6152, 1994.
25. Sakai S, Toguchida J, Ohtani N, Yandell DW, Rapaport R, Dryja TP: Allele-specific hypermethylation of the retinoblastoma tumor-suppressor gene. Am J Hum Genet 48:880-888, 1991.
26. de Bustros A, Nelkin BD, Silverman A, Ehrlich G, Poiesz B, Baylin SB: The short arm of chromosome 11 is a "hot spot" for hypermethylation in human neoplasia. Proc Natl Acad Sci USA 85:5693-5697, 1988.
27. Ottaviano YL, Issa JP, Parl FF, Smith HS, Baylin SB, Davidson NE: Methylation of the estrogen receptor gene CpG island marks loss of estrogen receptor expression in human breast cancer cells. Cancer Res 54:2552-2555, 1994.
28. Makos M, Nelkin BD, Reiter RE, Gnarra JR, Brook J, Isaacs W, Linehan M, Baylin SB: Regional DNA hypermethylation at D17S5 precedes 17p structural changes in the progression of renal tumors. Cancer Res 53:2719-2722, 1993.
29. Herman JG, Latif F, Weng YK, Lerman MI, Zbar B, Liu S, Samid D, Duan DSR, Gnarra JR, Linehan WM, Baylin SB: Silencing of the VHL tumor-suppressor gene by DNA methylation in renal carcinoma. Proc Natl Acad Sci USA 91:9700-9704, 1994.
30. Bestor TH: Methylation patterns in the vertebrate genome. [Review.] J NIH Res 6:57-60, 1993.
31. Bird AP: CpG-rich islands and the function of DNA methylation. [Review.] Nature 321:209-213, 1986.
32. Li E, Bestor TH, Jaenisch R: Targeted mutation of the DNA methyltransferase gene results in embryonic lethality. Cell 69:915-926, 1992.
33. Bedford MT, van Helden PD: Hypomethylation of DNA in pathological conditions of the human prostate. Cancer Res 47:5274-5276, 1987.
34. Ohtani-Fujita N, Fujita T, Aoike A, Osifchin NE, Robbins PD, Sakai T: CpG methylation inactivates the promoter activity of the human retinoblastoma tumor-suppressor gene. Oncogene 8:1063-1067, 1993.
35. Magewu AN, Jones PA: Ubiquitous and tenacious methylation of the CpG site in codon 248 of the p53 gene may explain its frequent appearance as a mutational hot spot in human cancer. Mol Cell Biol 14:4225-4232, 1994.
36. Antequera F, Boyes J, Bird A: High levels of de novo methylation and altered chromatin structure at CpG islands in cell lines. Cell 62:503-514, 1990.
37. Jarrard JD, Ewing CM, Morton RA, Bova GS, Isaacs WB: High levels of de novo methylation at CpG islands are found in the human prostate. J Urol 153:344a, 1995.
38. Morton RA, Bova GS, Isaacs WB: Hypermethylation of chromosome 17p13.3 in human adenocarcinoma of the prostate. J Urol 149:376a, 1993.
39. Makos M, Nelkin BD, Lerman MI, Latif F, Zbar B, Baylin SB: Distinct hypermethylation patterns occur at altered chromosome loci in human lung and colon cancer. Proc Natl Acad Sci USA 89:1929-1933, 1992.
40. Makos M, Nelkin BD, Chazin VR, Cavenee WK, Brodeur GM, Baylin SB: DNA hypermethylation is associated with 17p allelic loss in neural tumors. Cancer Res 53:2715-2718, 1993.
41. Cairns P, Polascik TJ, Eby Y, Sidransky D: High frequency of homozygous deletion at p16/CDKN2 in primary human tumors. Nature Genet 11(2):210-212, 1995.
42. Serrano M, Hannon GJ, Beach D: A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. [See comments.] Nature 366:704-707, 1993.
43. Jarrard DF, Ewing CM, Herman JG, Bova GS, Baylin SB, Isaacs WB: DNA methylation of p16(MTS1) in prostate cancer. (unpublished data), 1995.
44. Sasaki H, Jones PA, Chaillet JR, Ferguson-Smith AC, Barton SC, Reik W, Surani MA: Parental imprinting: potentially active chromatin of the repressed maternal allele of the mouse insulin-like growth factor II (Igf2) gene. Genes Dev 6:1843-1856, 1992.
45. Ogawa O, Eccles MR, Szeto J, McNoe LA, Yun K, Maw MA, Smith PJ, Reeve AE: Relaxation of insulin-like growth factor II gene imprinting implicated in Wilms' tumour. Nature 362:749-751, 1993.
46. Suzuki H, Veda R, Takahashi T: Altered imprinting in lung cancer. [Letter.] Nature Genet 6:332-333, 1994.
47. Jarrard DF, Bussemakers MG, Bova GS, Isaacs WB: A regional loss of imprinting of the insulin-like growth factor ii gene occurs in human prostate tissue. Clin Cancer Res 1:1471-1478, 1995.
48. Issa JP, Vertino PM, Wu J, Sazawal S, Celano P, Nelkin BD, Hamilton SR, Baylin SB: Increased cytosine DNA-methyltransferase activity during colon cancer progression. J Natl Cancer Inst 85:1235-1240, 1993.
49. Laird PW, Jackson-Grusby L, Fazeli A, Dickinson SL, Jung WE, Li E, Weinberg RA, Jaenisch R: Suppression of intestinal neoplasia by DNA hypomethylation. Cell 81:197-205, 1995.
50. MacLeod RA, Szyf M: Expression of antisense to DNA methyltransferase mRNA induces DNA demethylation and inhibits tumorigenesis. J Biol Chem 270:8037-8043, 1995.
51. Taylor SM: 5-Aza-2′-deoxycytidine: cell differentiation and DNA methylation. Leukemia 7(suppl 1):3-8, 1993.
52. Zagris N, Podimatas T: 5-Azacytidine changes gene expression and causes developmental arrest of early chick embryo. Int Dev Biol 38:741-744, 1994.
53. Strohmeyer TG, Slamon DJ: Proto-oncogenes and tumor suppressor genes in human urological malignancies. [Review.] J Urol 151:1479-1497, 1994.
54. Netto GJ, Humphrey PA: Molecular biologic aspects of human prostatic carcinoma. Am J Clin Pathol 102:s57-s64, 1994.
55. Peehl DM, Wehner N, Stamey TA: Activated Ki-ras oncogene in human prostatic adenocarcinoma. Prostate 10:281-289, 1987.
56. Carter BS, Ewing CM, Ward WS, Treiger BF, Aalders TW, Schalken JA, Epstein JJ, Isaacs WB: Allelic loss of chromosomes 16q and 10q in human prostate cancer. Proc Natl Acad Sci USA 87:8751-8755, 1990.
57. Bova GS, Carter BS, Bussemakers MJ, Emi M, Fujiwara Y, Kyprianou N, Jacobs SC, Robinson JC, Epstein JI, Walsh PC, Isaac WB: Homozygous deletion and frequent allelic loss of chromosome 8p22 loci in human prostate cancer. Cancer Res 53:3869-3873, 1993.
58. Ullrich JS, Anderson CW, Mercer WE, Appella E: The p53 tumor suppressor protein, a modulator of cell proliferation. J Biol Chem 267(22):15259-15262, 1992.
59. Isaacs WB, Carter BS, Ewing CM: Wild-type p53 suppresses growth of human prostate cancer cells containing mutant p53 alleles. Cancer Res 51:4716-4720, 1991.
60. Voeller HJ, Sugars LY, Pretlow T, Gelmann EP: p53 oncogene mutations in human prostate cancer specimens. J Urol 151:492-495, 1994.
61. Moyretlalle C, Marcais C, Jacquemier J, Moles JP, Daver A, Soret JY, Jeanteur P, Ozturk M, Theillet C: RAS, P53 and HPV status in benign and malignant prostate tumors. Int J Cancer 64:124-129, 1995.
62. Dinjens WM, van der Weiden MM, Schroeder FH, Bosman FT, Trapman J: Frequency and characterization of p53 mutations in primary and metastatic human prostate cancer. Int J Cancer 56:630-633, 1994.
63. Chi SG, deVere White RW, Meyers FJ, Siders DB, Lee F, Gumerlock PH: p53 in prostate cancer: Frequent expressed transition mutations. J Natl Cancer Inst 86:926-933, 1994.
64. Hall MC, Navone NM, Troncoso P, Pollack A, Zagars GK, Voneschenbach AC, Conti CJ, Chung LWK: Frequency and characterization of p53 mutations in clinically localized prostate cancer. Urology 45:470-475, 1995.
65. Bookstein R, MacGrogan D, Hilsenbeck SG, Sharkey F, Allred DC: p53 is mutated in a subset of advanced-stage prostate cancers. Cancer Res 53:3369-3373, 1993.
66. Visakorpi T, Kallioniemi OP, Heikkinen A, Koivula T, Isola J: Small subgroup of aggressive, highly proliferative prostatic carcinomas defined by p53 accumulation. J Natl Cancer Inst 84:883-887, 1992.
67. Navone NM, Troncoso P, Pisters LL, Goodrow TL, Palmer JL, Nichols WW, von Eschenbach AC, Conti C: p53 protein accumulation and gene mutation in the progression of human prostate carcinoma. J Natl Cancer Inst 85:1657-1669, 1993.
68. Goodrich DW, Wang NP, Qian YW, Lee EY, Lee WH: The retinoblastoma gene product regulates progression through the G1 phase of the cell cycle. Cell 67:293-301, 1991.
69. Bookstein R, Shew JY, Chen PL, Scully P, Lee WH: Suppression of tumorigenicity of human prostate carcinoma cells by replacing a mutated RB gene. Science 247:712-715, 1990.
70. Sarkar FJ, Sakr W, Li YW, Macoska J, Ball DE, Crissman JD: Analysis of retinoblastoma (RB) gene deletion in human prostatic carcinomas. Prostate 21:145-152, 1992.
71. Brooks JD, Bova GS, Isaacs WB: Retinoblastoma gene, prostate cancer, and allelic loss of the retinoblastoma gene in primary human prostatic adenocarcinomas. Prostate 26:35-39, 1995.
72. Gao X, Zacharek A, Grignon D, Liu H, Sakr W, Porter AT, Chen YQ, Honn KV: High frequency of loss of expression and allelic deletion of the apc and mcc genes in human prostate cancer. Int J Oncol 6:111-117, 1995.
73. Brewster SF, Browne S, Brown KW: Somatic allelic loss at the DCC, APC, nm23-H1 and p53 tumor suppressor gene loci in human prostatic carcinoma. J Urol 151:1073-1077, 1994.
74. Ionov Y, Peinado MA, Malkhosyan S, Shibata D, Perucho M: Ubiquitous somatic mutations in simple repeated sequences reveal a new mechanism for colonic carcinogenesis. Nature 363:558-561, 1993.
75. Bussemakers MJG, Bova GS, Schoenberg MP, Hakimi JM, Barrack Er, Isaacs WB: Microsatellite instability in human prostate cancer. J Urol 151:469A, 1995.
76. Gao X, Wu N, Grignon D, Zacharek A, Liu H, Salkowski A, Li G, Sakr W, Sarkar F, Porter AT: High frequency of mutator phenotype in human prostatic adenocarcinoma. Oncogene 9:2999-3003, 1994.
77. Quinn AG, Healy E, Rehman I, Sikkink S, Rees JL: Microsatellite instability in human nonmelanoma and melanoma skin cancer. J Invest Dermatol 104:309-312, 1995.
78. Eschleman JR, Lang EZ, Bowerfind GK, Parsons R, Vogelstein B, Willson JKV, Veigl ML, Sedwick WD, Markowitz SD: Increased mutation rate at the hprt locus accompanies microsatellite instability in colon cancer. Oncogene 10:33-37, 1995.
79. Dong JT, Lamb PW, Rinkerschaeffer CW, Vukanovic J, Ichikawa T, Isaacs JT, Barrett JC: KAI1, a metastasis suppressor gene for prostate cancer on human chromosome 11p11.2. Science 268:884-886, 1995.
80. Isaacs WB, Bova GS, Morton RA, Bussemakers MJG, Brooks JD, Ewing CM: Molecular genetics and chromosomal alterations in prostate cancer. Cancer 75:2004-2012, 1995.
81. Graff JR, Herman JG, Lapidus RG, Chopia H, Xu R, Jarrard DF, Isaacs WB, Pitha PM, Davidson NE, Baylin SB: E-cadherin expression is silenced by DNA hypermethylation in human breast and prostate cancers. Cancer Res 55:5195-5199, 1995.
82. Kunimi K, Bergerheim US, Larsson IL, Ekman P, Collins VP: Allelotyping of human prostatic adenocarcinoma. Genomics 11:530-536, 1991.
83. MacGrogan D, Levy A, Bostwick D, Wagner M, Wells D, Bookstein R: Loss of chromosome arm 8p loci in prostate cancer: mapping by quantitative allelic imbalance. Genes Chromosom Cancer 10:151-159, 1994.
84. Wolman SR, Pauley RJ, Mohamed AN, Dawson PJ, Visscher DW, Sarkar FH: Genetic markers as prognostic indicators in breast cancer. Cancer 70:1765-1774, 1992.
85. Emi M, Fujiwara Y, Nakajima T, Tsuchiya E, Tsuda H, Hirohashi S, Maeda Y, Tsuruta K, Miyaki M, Nakamura Y: Frequent loss of heterozygosity for loci on chromosome 8p in hepatocellular carcinoma, colorectal cancer, and lung cancer. Cancer Res 52:5368-5372, 1992.
86. Brothman AR, Peehl DM, Patel AM, McNeal JE: Frequency and pattern of karyotypic abnormalities in human prostate cancer. Cancer Res 50:3795-3802, 1990.
87. Visakorpi T, Kallioniemi AH, Syvanen AC, Hyytinen ER, Karhu R, Tammela T, Isola JJ, Kallioniemi OP: Genetic changes in primary and recurrent prostate cancer by comparative genomic hybridization. Cancer Res 55:342-347, 1995.
88. Cher ML, Bova GS, Isaacs WB, Jensen RH: Combined Southern analysis, microsatellite analysis, and comparative genomic hybridization analysis of advanced prostate cancers. J Urol 153(4):271A, 1995.